EMG
AGIO icon

Ellington Management Group’s Agios Pharmaceuticals AGIO Stock Holding History

Ellington Management Group’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-5,300
Closed -$215K – 251
2016
Q1 		$215K Buy
+5,300
New +$227K 0.09% 362

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ellington Management Group's AGIO Position: Q2 2016 in Review

Ellington Management Group sold out of Agios Pharmaceuticals (AGIO) in Q2 2016, closing a stake of 5,300 shares — an estimated $215K sold.

Ellington Management Group first reported a position in AGIO in Q1 2016 and held it in 1 quarter. The position peaked at $215K in Q1 2016. 155 funds tracked by Wall St. Rank hold AGIO as of Q2 2016.

  • Ellington Management Group reported no remaining Agios Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Ellington Management Group sold 5,300 Agios Pharmaceuticals shares in Q2 2016, an estimated $215K.
  • Ellington Management Group first reported a position in Agios Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • Ellington Management Group's Agios Pharmaceuticals position peaked at $215K in Q1 2016.
  • 155 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2016.

Based on Ellington Management Group's 13F filing for Q2 2016, filed 15 Aug 2016.